Valuation: Becton, Dickinson and Company

Market Cap 49.29B 42.97B 40.47B 36.86B 69.11B 4,722B 69.19B 485B 187B 2,405B 185B 181B 7,762B P/E 2026 *
34.9x
P/E 2027 * 19.4x
Enterprise Value 65.17B 56.82B 53.52B 48.74B 91.38B 6,244B 91.49B 641B 247B 3,180B 245B 239B 10,263B EV / Sales 2026 *
3.38x
EV / Sales 2027 * 3.2x
Free-Float
73.18%
Yield 2026 *
2.17%
Yield 2027 * 2.21%
Manager TitleAgeSince
Chief Executive Officer 53 28/01/2020
Director of Finance/CFO 44 05/12/2025
Compliance Officer - 01/02/2023
Director TitleAgeSince
Director/Board Member 75 24/09/2002
Director/Board Member 71 26/07/2010
Chairman 53 28/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-18.36% - - 49.29B
+0.10%-0.27%-24.75%+3.92% 178B
-0.09%-1.89%-2.74%+14.38% 118B
+2.08%-3.74%+8.74%+69.80% 58.92B
-0.24%-1.35%-3.28%-31.92% 49.29B
-0.22%-0.37%+10.27%+42.75% 48.17B
-0.50%+4.82%+27.69%-0.36% 33.72B
+0.77%-2.30% - - 27.76B
+0.63%+2.54%+44.41%-2.69% 25.5B
+1.77%+9.57%+9.06%-13.10% 22.1B
Average +0.43%+1.65%+8.68%+10.35% 62.32B
Weighted average by Cap. +0.26%+0.95%-3.01%+12.42%

Financials

2026 *2027 *
Net sales 19.26B 16.79B 15.82B 14.4B 27.01B 1,845B 27.04B 189B 73.01B 940B 72.35B 70.75B 3,033B 19.73B 17.21B 16.2B 14.76B 27.67B 1,890B 27.7B 194B 74.8B 963B 74.12B 72.48B 3,108B
Net income 1.44B 1.25B 1.18B 1.07B 2.01B 138B 2.02B 14.13B 5.45B 70.11B 5.4B 5.28B 226B 2.34B 2.04B 1.92B 1.75B 3.28B 224B 3.28B 23.01B 8.87B 114B 8.79B 8.59B 368B
Net Debt 15.88B 13.85B 13.04B 11.88B 22.27B 1,522B 22.3B 156B 60.21B 775B 59.67B 58.35B 2,502B 13.95B 12.16B 11.46B 10.43B 19.56B 1,337B 19.59B 137B 52.88B 681B 52.41B 51.25B 2,197B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!